📰 Immunotech Inc News
Immunotech Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunotech Inc. Real-time updates on events, politics, business and more.
May 30, 2024
AIM ImmunoTech (NYSE:AIM – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Earnings and Valuation This table compares […]
May 29, 2024
AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report)’s stock price traded down 9.1% on Tuesday . The company traded as low as $0.35 and last traded at $0.35. 344,384 shares changed hands during trading, an increase of 68% from the average session volume of 205,318 shares. The stock had previously closed at $0.39. AIM ImmunoTech […]
May 16, 2024
The Biden campaign and other Democrats believe they have several options to get the 270 Electoral College votes needed to win another four years in office. But retaining Michigan, Pennsylvania and... -May 16, 2024 at 06:20 am EDT - MarketScreener
May 6, 2024
AIM ImmunoTech Inc. (NYSE: AIM) shares poked ahead to begin the first full week of May, having announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed ...
May 6, 2024
OCALA, Fla., May 06, 2024 -- AIM ImmunoTech Inc. today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® , AIM’s dsRNA product candidate being...
April 30, 2024
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy...
April 29, 2024
Next safety cohort to begin escalated dosing soon...
April 29, 2024
Investegate announcements from AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
April 25, 2024
OCALA, Fla., April 25, 2024 -- AIM ImmunoTech Inc. , today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief...
April 24, 2024
In recent months, a conversation has emerged as to whether Delaware should remain the favored state of incorporation for business entities. Indeed, many of our clients have asked us...